Every material Form 8-K Arcadia Biosciences, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
At the September 10, 2026 annual meeting, stockholders approved the 2026 Omnibus Equity Incentive Plan, which succeeds the 2015 plan that expired in 2025, and approved an amendment allowing a reverse stock split of 1-for-2 to 1-for-10 if the board chooses to effect one before June 30, 2027. Stockholders also elected Gregory D. Waller as a Class II director and approved share issuance on exercise of Series A-1 Preferred Investment Options. The filing does not say whether the board will use the reverse split authority.
Equity plan approved with 326,188 votes for, 149,113 against and 7,889 abstentions
Reverse split authority approved with 1,120,937 votes for and 138,084 against, usable until June 30, 2027
Gregory D. Waller elected Class II director with 377,954 votes for and 105,236 withheld, serving until 2029
Shares present at the meeting totaled 1,259,315, about 52.3% of shares outstanding on the record date
Arcadia Biosciences received a Nasdaq letter dated August 31, 2026, saying its stockholders' equity of $633,000 at June 30, 2026, was below the $2.5 million minimum for continued listing on the Nasdaq Capital Market. The company's common stock will continue to trade on the Nasdaq Capital Market for now, but the company must submit a compliance plan, and there is no assurance Nasdaq will accept it.
Reported stockholders' equity was $633,000 as of June 30, 2026, versus the $2.5 million minimum under Nasdaq Listing Rule 5550(b)(1).
The company does not meet Nasdaq's alternative market value or net income standards either.
The compliance plan is due to Nasdaq by October 15, 2026; if accepted, Nasdaq may grant up to 180 calendar days to show compliance.
If Nasdaq rejects the plan, the company may appeal to a Nasdaq Hearings Panel, which ordinarily stays any suspension or delisting action.
Arcadia Biosciences reported second-quarter 2026 revenue of $1.4 million, down 1% from a year earlier, and a net loss attributable to common stockholders of $6.3 million, up from $4.5 million. The company attributed the revenue shortfall to low inventory and longer-than-expected shipping times, and the larger loss to non-operating items including a $5.4 million valuation loss on its June 2026 private placement and a $2.8 million unrealized loss on its Above Food stock.
Q2 2026 total revenues were $1.443 million versus $1.455 million in Q2 2025.
Q2 2026 net loss per share was $2.09, compared with $3.26 in Q2 2025.
The company raised $4 million in gross proceeds through a June 2026 private placement and reported $4.2 million in cash at June 30, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Arcadia Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →